- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00975429
Study Using WST11 in Patients With Localized Prostate Cancer
Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer
The aim of this trial is to determine the optimal treatment conditions to achieve prostate cancer tumour ablation and to assess the effects of WST11-mediated Vascular-Targeted Photodynamic therapy (VTP) treatment in patients with localized prostate cancer.
The secondary objectives are to assess the safety and quality of life following WST11-mediated VTP treatment,to assess the effects,safety and quality of life following a second WST11-mediated VTP treatment; and to explore optimisation techniques to reduce the duration of the VTP procedure.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Angers, France
- Centre Hospitalier Universitaire (Chu)
-
Lille, France
- Hôpital Claude Huriez
-
Paris, France
- Institut Mutualiste Montsouris(IMM)
-
-
-
-
-
Eindhoven, Netherlands
- Catharina Ziekenhuis
-
-
-
-
-
Frimley, United Kingdom
- Frimley Park Hospital NHS Trust
-
London, United Kingdom
- University College London Hospital (UCLH)
-
London, United Kingdom
- Kings College Hospital (KCH)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men over 18 years of age;
- Diagnosed with prostate cancer and eligible for active surveillance;
- No prior treatment for prostate cancer;
- Prostate Cancer Stage up to cT2b - N0/Nx - M0/Mx (rT2c and pT2c are acceptable)
- Gleason score ≤ 3+3 For patients characterized with prostate mapping (transperineal template guided biopsy at 5mm intervals) a secondary pattern 4 is acceptable provided that it is not present in more than 3 cores from each side of the prostate and is no more than 3 mm cancer core length.
- PSA < 10 ng/mL;
- Signed Informed Consent Form.
Exclusion Criteria:
- Any condition or history of illness or surgery that, in the opinion of the investigator and/or the Sponsor, might confound the results of the study or pose additional risks to the patient.
- All patients whose current pre-operative cardiac evaluation does not show their fitness for a procedure requiring general anesthesia;
- Patients with a prior history of viral or alcoholic hepatitis, and other patients felt to be at risk for hepatotoxicity including concomitant use of potentially hepatotoxic medications or dietary supplements;
- Patients with a history of inflammatory bowel disease or other factors which may increase the risk of fistula formation;
- Men who have received any hormonal manipulation (excluding 5-alpha reductase inhibitors) or androgen supplements within the previous 6 months;
- Men previously treated by radiation therapy (external therapy or brachytherapy) or chemotherapy or any therapy for prostate cancer;
- Men who have received or are receiving chemotherapy for prostate carcinoma or other significant cancer;
- Men who have undergone previous TURP (trans-urethral resection of the prostate);
- Men who are currently receiving any medications having potential photosensitizing effects (e.g. tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics and griseofulvin).
- Men who are receiving anticoagulant drugs (e.g.: coumadin, warfarin).
- Patient who stopped long term treatment of acetylsalicylic acid (aspirin) or other anti platelets agents less than 15 days before the procedure;
- Patient suspected of Disseminated Intravascular Coagulation (DIC) as defined by the presence of three out of the five following criteria: platelets <LLN, PT >ULN, aPTT >ULN, fibrinogen<LLN, D-Dimer >ULN
- History of non compliance with medical therapy and medical recommendations or an unwillingness or inability to complete patient self-administered questionnaires;
- Participation in a clinical study or receipt of an investigational treatment within the past 3 months;
- A history of porphyria;
- A history of sun hypersensitivity or photosensitive dermatitis;
- Renal disorders (blood creatinine > 1.5 x ULN) or known post mictional residue > 150cc
- Hepatic disorders (transaminases > ULN, bilirubin > ULN,). In case of slight abnormalities, another exam should be performed. If the results are within normal ranges, then the patient can be included;
- Hematological disorders (white cells < 2500/mm3, neutrophils < 1500/mm3, platelets < 140.000/mm3, Hb < 8 g/dL);
- Patient with contra-indication to MRI (such as pace maker, metal prosthesis, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: WST11 - 4mg (TOOKAD® Soluble)
4mg/kg Treatment with WST11-mediated VTP
|
The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers.
The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance.
The tumour location is established using transrectal biopsy and MR imaging.
The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
Other Names:
The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers.
The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance.
The tumour location is established using transrectal biopsy and MR imaging.
The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
Other Names:
|
Experimental: WST11 - 6mg
6mg/kg Treatment with WST11-mediated VTP
|
The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers.
The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance.
The tumour location is established using transrectal biopsy and MR imaging.
The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
Other Names:
The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers.
The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance.
The tumour location is established using transrectal biopsy and MR imaging.
The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Negative biopsy in the treated lobes
Time Frame: Month 6
|
Month 6
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum PSA levels and PSA changes after treatment compared to baseline.
Time Frame: Month 1, Month 3 & Month 6
|
Month 1, Month 3 & Month 6
|
Volume of hypoperfusion area shown by dynamic gadolinium MRI.
Time Frame: Day 7, Month 6
|
Day 7, Month 6
|
Adverse events, ECG (12-lead),vital signs,clinical laboratory evaluations, physical examination.
Time Frame: Screening-Month 6
|
Screening-Month 6
|
Quality of life IPSS; IIEF
Time Frame: Month 1, Month 3 & Month 6
|
Month 1, Month 3 & Month 6
|
Optimisation of the procedure
Time Frame: Day 1
|
Day 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark Emberton, Professor, University College London Hospital (UCLH)
- Principal Investigator: Gordon MUIR, MD, Kings College Hospital (KCH)
- Principal Investigator: Neil BARBER, MD, Frimley Park Hospital NHS Trust
- Principal Investigator: Michel de Wildt, MD, Catharina Ziekenhuis
- Principal Investigator: Abdel-Rahmène AZZOUZI, Professor, Centre Hospitalier Unniversitaire Angers(CHU)
- Principal Investigator: Eric BARRET, MD, Institut Mutualiste Montsouris (IMM)
- Principal Investigator: Arnauld VILLERS, Professor, Hôpital Claude-Huriez
Publications and helpful links
General Publications
- Azzouzi AR, Barret E, Bennet J, Moore C, Taneja S, Muir G, Villers A, Coleman J, Allen C, Scherz A, Emberton M. TOOKAD(R) Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. World J Urol. 2015 Jul;33(7):945-53. doi: 10.1007/s00345-015-1505-8. Epub 2015 Feb 25.
- Lebdai S, Villers A, Barret E, Nedelcu C, Bigot P, Azzouzi AR. Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad(R) Soluble focal treatment for localized prostate cancer. World J Urol. 2015 Jul;33(7):965-71. doi: 10.1007/s00345-015-1493-8. Epub 2015 Jan 23.
- Azzouzi AR, Barret E, Moore CM, Villers A, Allen C, Scherz A, Muir G, de Wildt M, Barber NJ, Lebdai S, Emberton M. TOOKAD((R)) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int. 2013 Oct;112(6):766-74. doi: 10.1111/bju.12265.
- Azzouzi AR, Lebdai S, Benzaghou F, Stief C. Vascular-targeted photodynamic therapy with TOOKAD(R) Soluble in localized prostate cancer: standardization of the procedure. World J Urol. 2015 Jul;33(7):937-44. doi: 10.1007/s00345-015-1535-2. Epub 2015 Mar 19.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLIN902 PCM203
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on WST11
-
Steba Biotech S.A.CompletedProstate CancerFrance, United Kingdom, Canada
-
Steba Biotech S.A.TerminatedNon-Small Cell Lung CancerFrance
-
Steba Biotech S.A.TerminatedCholangiocarcinomaFrance
-
Steba Biotech S.A.TerminatedMacular Degeneration | Choroidal NeovascularizationUnited States, France
-
Steba Biotech S.A.PrimeVigilance; ICON plcRecruitingTransitional Cell Cancer of Renal Pelvis and UreterUnited States, Israel, Spain, Italy, France, Germany, Austria
-
Steba Biotech S.A.WithdrawnLocalized Prostate CancerUnited States
-
Steba Biotech S.A.CompletedEfficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer (PCM304)Prostate CancerMexico, Panama, Peru
-
Steba Biotech S.A.CompletedProstate CancerSpain, France, Germany, Netherlands, United Kingdom, Belgium, Finland, Italy, Sweden, Switzerland
-
University of OxfordSteba Biotech S.A.Terminated
-
Steba Biotech S.A.Active, not recruitingLocalized Prostate CancerUnited States